On Wednesday, Target Corp. (TGT - Free Report) is the just the latest brick-and-mortar retailer to report dismal holiday season sales, and its stock took a huge hit as a result. In the financial sector, Goldman Sachs (GS - Free Report) and Citigroup (C - Free Report) were both on the move after reporting fourth-quarter earnings before the bell today. Goldman Sachs beat Street estimates on both the top and bottom lines, whole Citi posted mixed results.
Zacks #1 (Strong Buy) Biggest Movers
Value: AK Steel
Growth: United States Steel Corp. (X - Free Report)
Momentum: X
VGM: AKS
Major Indexes
DOW: 19,804.43 / -22.34 / -0.11%
S&P 500: 2,271.92 / +4.03 / +0.18%
NASDAQ: 5,555.56 / +16.83 / +0.30%
Top Headlines
Target Slides 6% on Disappointing Holiday Sales
Target is the latest retailer to report disappointing holiday sales, and its stock fell around 6% as a result. The retailer said that comparable sales fell 1.3% in November and December; any gains seen in its online business were outshone by increased difficulty in getting customers into its stores, as well as stiff price competition from rivals.
Here’s Why CoLucid Pharma is Skyrocketing 32% Today
Shares of biopharmaceutical company CoLucid Pharmaceuticals skyrocketed around 32% after Eli Lilly and Co. announced it is buying the company for a whopping $960 million. With the deal, Eli Lilly is gaining access to CoLucid’s experimental treatment for migraine, a large but under-treated condition that affects roughly 36 million Americans.
Bull of the Day: B&G Foods (BGS - Free Report)
B&G Foods (BGS - Free Report) is a food products company with a huge portfolio of well-known brands. B&G continues to grow organically and through acquisitions, and after better than expected results and revised guidance, analysts have raised estimates for the company. For this reason, B&G is Zacks’ Bull of the Day.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
On Wednesday, Target Corp. (TGT - Free Report) is the just the latest brick-and-mortar retailer to report dismal holiday season sales, and its stock took a huge hit as a result. In the financial sector, Goldman Sachs (GS - Free Report) and Citigroup (C - Free Report) were both on the move after reporting fourth-quarter earnings before the bell today. Goldman Sachs beat Street estimates on both the top and bottom lines, whole Citi posted mixed results.
Zacks #1 (Strong Buy) Biggest Movers
Value: AK Steel
Growth: United States Steel Corp. (X - Free Report)
Momentum: X
VGM: AKS
Major Indexes
DOW: 19,804.43 / -22.34 / -0.11%
S&P 500: 2,271.92 / +4.03 / +0.18%
NASDAQ: 5,555.56 / +16.83 / +0.30%
Top Headlines
Target Slides 6% on Disappointing Holiday Sales
Target is the latest retailer to report disappointing holiday sales, and its stock fell around 6% as a result. The retailer said that comparable sales fell 1.3% in November and December; any gains seen in its online business were outshone by increased difficulty in getting customers into its stores, as well as stiff price competition from rivals.
Here’s Why CoLucid Pharma is Skyrocketing 32% Today
Shares of biopharmaceutical company CoLucid Pharmaceuticals skyrocketed around 32% after Eli Lilly and Co. announced it is buying the company for a whopping $960 million. With the deal, Eli Lilly is gaining access to CoLucid’s experimental treatment for migraine, a large but under-treated condition that affects roughly 36 million Americans.
Bull of the Day: B&G Foods (BGS - Free Report)
B&G Foods (BGS - Free Report) is a food products company with a huge portfolio of well-known brands. B&G continues to grow organically and through acquisitions, and after better than expected results and revised guidance, analysts have raised estimates for the company. For this reason, B&G is Zacks’ Bull of the Day.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GS - FREE
Get the latest research report on C - FREE
Get the latest research report on TGT - FREE
Get the latest research report on X - FREE
Get the latest research report on BGS - FREE